Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 3:40:100952.
doi: 10.1016/j.gore.2022.100952. eCollection 2022 Apr.

Gynecologic oncology HPV vaccination practice patterns: Investigating practice barriers, knowledge gaps and opportunities for maximizing cervical cancer prevention

Mali K Schneiter  1 , Kimberly Levinson  1 , Anne F Rositch  2 , Rebecca L Stone  1 , Amanda Nickles Fader  1 , James Stuart Ferriss  1 , Stephanie L Wethington  1 , Anna L Beavis  1
Affiliations
Review

Gynecologic oncology HPV vaccination practice patterns: Investigating practice barriers, knowledge gaps and opportunities for maximizing cervical cancer prevention

Mali K Schneiter et al. Gynecol Oncol Rep. .

Abstract

Objective: HPV vaccination is an important form of cancer prevention. Gynecologic oncologists have an opportunity to improve adult vaccination rates. We aimed to describe current HPV vaccination practices and barriers to vaccination reported by gynecologic oncologists.

Methods: An online survey was developed, pilot tested and sent to U.S. members of the Society of Gynecologic Oncology.

Results: Of the 226 respondents, most were female (73%), < 45 years old (64%) and practiced in urban (60%) and academic settings (69%). Ninety percent had recommended the HPV vaccine in the past year. Nearly half (47%) had facilitated vaccination by: administering the HPV vaccine in clinic (40%), stocking the vaccine (35%), or prescribing the vaccine (30%). Recommending the vaccine was associated with higher outpatient volume, practicing in the South vs. Northeast, and having higher levels of vaccine knowledge.Of the 90% who recommended the vaccine, 60% did not prescribe or know if they could prescribe the vaccine in their state. Prioritization of cancer treatment was the most commonly reported barrier to HPV vaccination (88%). Approximately half of providers reported other systems-level hinderances such as high cost of stocking the vaccine, clinic flow disruption, or uncertainty surrounding insurance coverage. Almost all recommenders offered the vaccine at HPV-related dysplasia (92%) or cancer (80%) visits, while only 24-50% offered it at non-HPV-related visits.

Conclusions: These survey results identify patient, provider, and systems-level barriers that could be targeted to help increase adult HPV vaccination in gynecologic oncology clinics.

Keywords: Barriers; Gynecologic oncologists; HPV vaccine; HPV vaccine champion; HPV-related Cancer prevention; Survey.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Frequency of barriers to successful HPV vaccination reported by gynecologic oncologists.
Fig. 2
Fig. 2
Clinical scenarios in which gynecologic oncologists who both recommended and had the ability to prescribe or administer the vaccine (n = 101) reported how likely they would be to offer the HPV vaccine. N/A = not applicable * Asked as yes, no, sometimes.
See this image and copyright information in PMC

References

    1. Lu P.-J., Hung M.-C., Srivastav A., Grohskopf L.A., Kobayashi M., Harris A.M., Dooling K.L., Markowitz L.E., Rodriguez-Lainz A., Williams W.W. Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018. MMWR Surveill. Summ. 2021;70(3):1–26. - PMC - PubMed
    1. Meites E., Szilagyi P.G., Chesson H.W., Unger E.R., Romero J.R., Markowitz L.E. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb. Mortal. Wkly Rep. 2019;68(32):698–702. - PMC - PubMed
    1. Administration USFaD, 2018. FDA approves expanded use Gardasil 9 to include individuals 27 through 45 years old 2018. p. https://www.fda.gov/news-events/press-announcements/fda-approves-expande....
    1. Human Papillomavirus Vaccination ACOG Committee Opinion Summary, Number 809. Obstet. Gynecol. 2020;136(2):435–436. - PubMed
    1. Lichter K., Krause D., Xu J., Tsai S.H.L., Hage C., Weston E., Eke A., Levinson K. Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis. Obstet. Gynecol. 2020;135(5):1070–1083. - PubMed

LinkOut - more resources